Head-to-head · WeighScore
Harbor vs NuuVim
The verdict
Harbor takes it — 71.8/100 to 71.1/100, but only just.
Harbor grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Harbor is a physician-led telehealth platform offering compounded semaglutide (from $99/mo) and compounded tirzepatide (from $149/mo) — among the lowest headline prices in the market. NuuVim is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Harbor | NuuVim |
|---|---|---|
| WeighScore | 71.8/100 | 71.1/100 |
| Grade | C | C |
| Scorecard rank | #87 | #101 |
| Semaglutide | $99/mo (starting dose, compounded) | $79/mo (all doses, compounded) |
| Tirzepatide | $149/mo (starting dose, compounded) | $133/mo (all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #87 · C
Strengths
- Compounded semaglutide from $99/mo and tirzepatide from $149/mo — among the lowest headline prices in the market
- LegitScript certified with 4.7-star rating, 94.6% success rate, and 10,000+ verified members
- 24/7 physician access with ongoing consultations, dosage adjustments, and free discreet shipping
- 12-Month Money Back Guarantee if you don't reach your weight-loss goal
- HSA/FSA eligible; no hidden fees, no insurance billed
Where it loses points
- Compounded medications are not FDA-approved; compounding pharmacy names not publicly disclosed
- Dietitian support offered only post-program (maintenance phase), not during active treatment
- State-specific consultation types vary; nationwide availability unconfirmed for all states
- No labs disclosed; patient portal is a third-party platform (mdintegrations), not native
- Newer brand; success rate and member counts are on-site claims, not third-party verified
Graded #101 · C
Strengths
- Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
- Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
- LegitScript Certified and HIPAA-compliant
- Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
- Operating legal entity disclosed: NuuVim LLC, Texas governing law
Where it loses points
- No founder, CEO, medical director, or pharmacist-in-charge named
- Refund and cancellation policy not surfaced on the site
- Compounded medications are not FDA-approved
- Doesn't disclose which pharmacy fills which drug or form
- FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.